Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (scDiabody-Fc) (SCDBF-144)

Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (scDiabody-Fc) is a fusion protein of two scDiabodies with an Fc region. In single-chain Diabodies, an additional connecting linker is introduced between chains of the anti-Csl/anti-CD3 diabody. The scDiabody with two specificities is further fused to the Fc domain to form BsAb with 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

Csl & CD3

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia

Targets

Target 1

Csl

Gene ID

3516

UniProt ID

Q06330

Alternative Names

SUH; csl; AOS3; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; RBPSUH; IGKJRB1; recombination signal binding protein for immunoglobulin kappa J region; RBPJ; Lag-1; Suppressor of hairless

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (scDiabody-Fc) (SCDBF-144). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (scDiabody-Fc) (CAT#: SCDBF-144)

Specifications

Targets

Customer Reviews and Q&As